Javier Terriente is a renowned scientist and entrepreneur with years of experience leading biotech companies. He is currently co-founder and Chief of Drug Development (CDD) at ZeClinics, a biotech company that uses zebrafish as a model for drug discovery and studying human diseases. Additionally, he is a co-founder and CSO at ZeCardio Therapeutics, a biotech company spun out from ZeClinics, that focuses on discovering therapies to treat cardiovascular diseases.

Javier holds a PhD in Molecular Biology from the Universidad Autónoma de Madrid and a Bachelor's degree in Biochemistry from the Universidad de Granada. He has a proven track record in his field, having conducted research and held postdoctoral fellowships at various prestigious institutions such as Medical Research Council, University of Sussex and Universitat Pompeu Fabra.

He is also actively involved in the Spanish biotech community as the Vice President of ASEBIO, the Spanish Association of Biotech Companies. Recognized as an expert in his field, he brings a wealth of knowledge and experience to his role within the organization.

Javier is a leader in the biotech industry, known for his innovative approach and commitment to discovering therapies that contribute to the improvement of global health. With his exceptional skills in drug development, scientific research, and business management, he continues to make significant contributions to his field.